Patents by Inventor Mikael Elofsson
Mikael Elofsson has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 10011628Abstract: Disclosed is tri- or tetravalent sialic acid derivatives comprising a core moiety to which 3 or 4 sialic acid residues are connected via a linker. Such derivatives inhibit the binding of adenovirus to human cells, whereby infections, such as epidemic keratoconjunctivitis, may be treated or prevented by administration of the tri- or tetravalent sialic acid derivatives.Type: GrantFiled: August 28, 2014Date of Patent: July 3, 2018Assignee: ADENOVIR PHARMA ABInventors: Niklas Arnberg, Rémi Caraballo, Mikael Elofsson
-
Publication number: 20160207955Abstract: Disclosed is tri- or tetravalent sialic acid derivatives comprising a core moiety to which 3 or 4 sialic acid residues are connected via a linker. Such derivatives inhibit the binding of adenovirus to human cells, whereby infections, such as epidemic keratoconjunctivitis, may be treated or prevented by administration of the tri- or tetravalent sialic acid derivatives.Type: ApplicationFiled: August 28, 2014Publication date: July 21, 2016Applicant: Adenovir Pharma ABInventors: Niklas Arnberg, Rémi Caraballo, Mikael Elofsson
-
Patent number: 8993622Abstract: The present invention provides new antiviral compounds and pharmacological compositions comprising these new compounds and their use in the prophylaxis, prevention and treatment of viral infections, particularly adenovirus and herpes virus infections.Type: GrantFiled: June 13, 2011Date of Patent: March 31, 2015Assignee: Eirium ABInventors: Göran Wadell, Karin Edlund, Marten Strand, Emma Andersson, Christopher Öberg, Mikael Elofsson, Ya-Fang Mei
-
Publication number: 20130210915Abstract: The present invention provides new antiviral compounds and pharmacological compositions comprising these new compounds and their use in the prophylaxis, prevention and treatment of viral infections, particularly adenovirus and herpes virus infections.Type: ApplicationFiled: June 13, 2011Publication date: August 15, 2013Inventors: Göran Wadell, Karin Edlund, Marten Strand, Emma Andersson, Christopher Öberg, Mikael Elofsson, Ya-Fang Mei
-
Publication number: 20100099674Abstract: A means for decreasing bacterial virulence in a mammal including man or in a plant by inhibition of the Type III secretion system at concentrations that do not prevent or substantially reduce bacterial growth comprises an N-substituted 7-quinolylmethyl amine, in particular one that is further substituted in 5- and 8-position on the quinoline ring. A corresponding therapeutic method and a pharmaceutical composition are also disclosed.Type: ApplicationFiled: March 18, 2008Publication date: April 22, 2010Applicant: Innate Pharmaceuticals ABInventor: Mikael Elofsson
-
Publication number: 20090099097Abstract: Peptide-based compounds including heteroatom-containing, three-membered rings efficiently and selectively inhibit specific activities of N-terminal nucleophile (Ntn) hydrolases. The activities of those Ntn having multiple activities can be differentially inhibited by the compounds described. For example, the chymotrypsin-like and PGPH activities of the 20S proteasome can be selectively inhibited with the inventive compounds. The peptide-based compounds include an electron withdrawing group adjacent to the ring functionality, and the peptide include at least three peptide units. Among other therapeutic utilities, the peptide-based compounds exhibit anti-inflammatory and inhibition of cell proliferation, involving therapeutic applications for these compounds.Type: ApplicationFiled: November 7, 2008Publication date: April 16, 2009Applicant: Yale UniversityInventors: Craig M. Crews, Mikael Elofsson, Ute Splittgerber, Kyung Bo Kim
-
Patent number: 7476650Abstract: Peptide-based compounds including heteroatom-containing, three-membered rings efficiently and selectively inhibit specific activities of N-terminal nucleophile (Ntn) hydrolases. The activities of those Ntn having multiple activities can be differentially inhibited by the compounds described. For example, the chymotrypsin-like and PGPH activities of the 20S proteasome can be selectively inhibited with the inventive compounds. The peptide-based compounds include an electron withdrawing group adjacent to the ring functionality, and the peptide include at least three peptide units. Among other therapeutic utilities, the peptide-based compounds exhibit anti-inflammatory and inhibition of cell proliferation, involving therapeutic applications for these compounds.Type: GrantFiled: June 17, 2004Date of Patent: January 13, 2009Assignee: Yale UniversityInventors: Craig M. Crews, Mikael Elofsson, Ute Splittgerber, Kyung Bo Kim
-
Publication number: 20040266664Abstract: Peptide-based compounds including heteroatom-containing, three-membered rings efficiently and selectively inhibit specific activities of N-terminal nucleophile (Ntn) hydrolases. The activities of those Ntn having multiple activities can be differentially inhibited by the compounds described. For example, the chymotrypsin-like and PGPH activities of the 20S proteasome can be selectively inhibited with the inventive compounds. The peptide-based compounds include an electron withdrawing group adjacent to the ring functionality, and the peptide include at least three peptide units. Among other therapeutic utilities, the peptide-based compounds exhibit anti-inflammatory and inhibition of cell proliferation, involving therapeutic applications for these compounds.Type: ApplicationFiled: June 17, 2004Publication date: December 30, 2004Applicant: Yale UniversityInventors: Craig M. Crews, Mikael Elofsson, Ute Splittgerber, Kyung Bo Kim
-
Patent number: 6831099Abstract: Peptide-based compounds including heteroatom-containing, three-membered rings efficiently and selectively inhibit specific activities of N-terminal nucleophile (Ntn) hydrolases. The activities of those Ntn having multiple activities can be differentially inhibited by the compounds described. For example, the chymotrypsin-like and PGPH activities of the 20S proteasome can be selectively inhibited with the inventive compounds. The peptide-based compounds include an electron withdrawing group adjacent to the ring functionality, and the peptide include at least three peptide units. Among other therapeutic utilities, the peptide-based compounds exhibit anti-inflammatory and inhibition of cell proliferation, involving therapeutic applications for these compounds.Type: GrantFiled: May 11, 2000Date of Patent: December 14, 2004Assignee: Yale UniversityInventors: Craig M. Crews, Mikael Elofsson, Ute Splittgerber, Ny Sin, Kyung Bo Kim